A5104272009- Sarcoidosis and Beryllium Toxicity Research
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- S100 Proteins and Annexins
- Pneumonia and Respiratory Infections
- Vasculitis and related conditions
- Viral Infections and Immunology Research
- Cardiovascular Effects of Exercise
- Pneumocystis jirovecii pneumonia detection and treatment
Mayo Clinic in Arizona
2024
Mayo Clinic
2024
WinnMed
2024
Cardiac sarcoidosis (CS) may result in systolic heart failure (heart with reduced ejection fraction [HFrEF]), but its response to guideline-directed medical therapy (GDMT) remains uncertain.
Cardiac sarcoidosis (CS) is a granulomatous disease that can manifest as conduction defects, ventricular arrhythmias, and heart failure. The diagnosis of CS inherently difficult due to variable presentations; such, endomyocardial biopsy often required but lacks sensitivity patchy myocardial involvement. Moreover, the diagnostic criteria arrhythmogenic cardiomyopathy overlap, particularly in right-side dominant or biventricular presentations, which further complicates an already challenging...
Background A multidisciplinary approach improves guideline‐directed medical therapy (GDMT) in systolic heart failure (HF), but its efficacy patients with HF due to cardiac sarcoidosis (CS) is unreported. Methods and Results In a retrospective cohort study, we reviewed 848 from our institutional CS clinics, identifying those diagnosis, (LVEF < 50%) at index evaluation, echocardiograms within 90 days 11‐36 months. Patients were stratified by participation pharmacist‐led medication...